This site may require a log-in in the near future. We are constantly being swamped by AI agents. If they continue to take down the site, we will be changing to requiring logins to access any item.

🍽️ pentamidine isethionate,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Antihistaminic Effects: Pheniramine maleate blocks the action of histamine, a substance in the body that contributes to allergic reactions. By inhibiting histamine receptors, pheniramine helps relieve symptoms such as sneezing, itching, watery eyes, and runny nose associated with allergies.

  2. Allergic Rhinitis: Pheniramine maleate is commonly used to alleviate symptoms of allergic rhinitis, also known as hay fever. It can help reduce nasal congestion, sneezing, itching, and runny nose caused by exposure to allergens such as pollen, dust mites, or pet dander.

  3. Allergic Conjunctivitis: Pheniramine maleate may be used to relieve symptoms of allergic conjunctivitis, an inflammation of the conjunctiva (the membrane covering the inner surface of the eyelids and the whites of the eyes) triggered by allergens. It can help alleviate itching, redness, and watering of the eyes.

  4. Allergic Skin Reactions: Pheniramine maleate can be effective in managing allergic skin reactions, including itching, hives (urticaria), and insect bites. It works by reducing histamine-induced itching and inflammation, providing relief from discomfort and promoting healing of the affected skin.

  5. Sedation: Pheniramine maleate has sedative properties and may cause drowsiness or sleepiness, particularly when taken at higher doses or in combination with other medications that have sedating effects. Patients should be cautioned against driving or operating machinery until they know how pheniramine affects them.

  6. Central Nervous System Effects: In addition to sedation, pheniramine maleate may cause other central nervous system effects, such as dizziness, confusion, or impaired coordination. These effects are generally mild and transient but may be more pronounced in some individuals.

  7. Dry Mouth: Pheniramine maleate can cause dryness of the mouth due to its anticholinergic effects, which reduce saliva production. Patients should stay well-hydrated and consider using sugar-free lozenges or chewing gum to alleviate dry mouth symptoms.

  8. Urinary Retention: In rare cases, pheniramine maleate may cause urinary retention, particularly in men with prostatic hypertrophy or individuals with bladder obstruction. Patients should be monitored for urinary symptoms and advised to seek medical attention if they experience difficulty urinating.

  9. Gastrointestinal Effects: Gastrointestinal side effects such as nausea, vomiting, or constipation may occur with pheniramine use, although they are relatively uncommon.

  10. Cardiovascular Effects: Pheniramine maleate has minimal effects on the cardiovascular system, but caution should be exercised in patients with pre-existing cardiovascular conditions, as antihistamines may rarely cause changes in heart rate or blood pressure.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations

βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of pentamidine isethionate,(prescription) On Probiotics

Rank Probiotic Impact
genus Bifidobacterium Reduces
species Bacteroides uniformis Reduces
species Bifidobacterium adolescentis Reduces
species Bifidobacterium longum Reduces
species Lacticaseibacillus paracasei Reduces
species Parabacteroides distasonis Reduces
subspecies Bifidobacterium longum subsp. infantis Reduces
subspecies Bifidobacterium longum subsp. longum Reduces

Bacteria Impacted by pentamidine isethionate,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

πŸ““ Direct Citations πŸ‘ͺπŸ‘Ά Indirect Citations Taxonomy Rank Effect
0 1 Dorea genus Decreases
0 1 Roseburia genus Decreases
0 1 Parabacteroides genus Decreases
0 1 Ruminococcus genus Decreases
0 1 Agathobacter genus Decreases
0 1 Bacteroides genus Decreases
0 1 Bifidobacterium genus Decreases
0 1 Bilophila genus Decreases
0 1 Clostridioides genus Decreases
0 1 Collinsella genus Decreases
0 1 Coprococcus genus Decreases
0 1 Eggerthella genus Decreases
0 1 Fusobacterium genus Decreases
0 1 Lachnospira genus Decreases
0 1 Lacrimispora genus Decreases
0 1 Mediterraneibacter genus Decreases
0 1 Odoribacter genus Decreases
0 1 Phocaeicola genus Decreases
0 1 Streptococcus genus Decreases
0 1 Veillonella genus Decreases
0 1 Clostridium genus Decreases
0 1 Segatella genus Decreases
0 1 Enterocloster genus Decreases
0 1 Blautia genus Decreases
0 1 Thomasclavelia genus Decreases
0 1 Lacticaseibacillus genus Decreases
0 1 Clostridium perfringens A no rank Decreases
0 1 Clostridium perfringens C no rank Decreases
0 1 Clostridium perfringens CPE no rank Decreases
0 1 Clostridium perfringens D no rank Decreases
0 1 Clostridium perfringens B no rank Decreases
0 1 Clostridium perfringens E no rank Decreases
1 0 Enterocloster bolteae species Decreases
1 0 [Ruminococcus] torques species Decreases
1 0 Agathobacter rectalis species Decreases
1 0 Bacteroides caccae species Decreases
1 0 Bacteroides fragilis species Decreases
1 0 Bacteroides ovatus species Decreases
1 0 Bacteroides thetaiotaomicron species Decreases
1 0 Bacteroides uniformis species Decreases
1 0 Bacteroides xylanisolvens species Decreases
1 0 Bifidobacterium adolescentis species Decreases
1 0 Bifidobacterium longum species Decreases
1 0 Bilophila wadsworthia species Decreases
1 0 Blautia obeum species Decreases
1 0 Clostridioides difficile species Decreases
1 0 Clostridium perfringens species Decreases
1 0 Collinsella aerofaciens species Decreases
1 0 Coprococcus comes species Decreases
1 0 Dorea formicigenerans species Decreases
1 0 Eggerthella lenta species Decreases
1 0 Fusobacterium nucleatum species Decreases
1 0 Lachnospira eligens species Decreases
1 0 Lacrimispora saccharolytica species Decreases
1 0 Lacticaseibacillus paracasei species Decreases
1 0 Mediterraneibacter gnavus species Decreases
1 0 Odoribacter splanchnicus species Decreases
1 0 Parabacteroides distasonis species Decreases
1 0 Parabacteroides merdae species Decreases
1 0 Phocaeicola vulgatus species Decreases
1 0 Roseburia hominis species Decreases
1 0 Roseburia intestinalis species Decreases
1 0 Ruminococcus bromii species Decreases
1 0 Segatella copri species Decreases
1 0 Streptococcus parasanguinis species Decreases
1 0 Streptococcus salivarius species Decreases
1 0 Thomasclavelia ramosa species Decreases
1 0 Veillonella parvula species Decreases
0 1 Bifidobacterium longum subsp. longum subspecies Decreases
0 1 Bifidobacterium longum subsp. infantis subspecies Decreases
0 1 Bifidobacterium longum subsp. suis subspecies Decreases
0 1 Lacticaseibacillus paracasei subsp. paracasei subspecies Decreases
0 1 Fusobacterium nucleatum subsp. nucleatum subspecies Decreases
0 1 Lacticaseibacillus paracasei subsp. tolerans subspecies Decreases
0 1 Bifidobacterium longum subsp. suillum subspecies Decreases

Impact of pentamidine isethionate,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Abdominal Aortic Aneurysm 0.9 0.9
Acne 0.6 0.9 -0.5
ADHD 5.4 0.9 5
Age-Related Macular Degeneration and Glaucoma 1.1 0.4 1.75
Allergic Rhinitis (Hay Fever) 2.8 2.4 0.17
Allergies 8.3 4.8 0.73
Allergy to milk products 1.4 1 0.4
Alopecia (Hair Loss) 1.6 1.6
Alzheimer's disease 7.2 7.7 -0.07
Amyotrophic lateral sclerosis (ALS) Motor Neuron 2.9 0.8 2.62
Ankylosing spondylitis 3.6 1.8 1
Anorexia Nervosa 1.6 3.2 -1
Antiphospholipid syndrome (APS) 1.5 0.3 4
Asthma 5.9 2.3 1.57
Atherosclerosis 2.1 2.8 -0.33
Atrial fibrillation 4.1 2.5 0.64
Autism 10.8 9.6 0.13
Autoimmune Disease 0.6 1 -0.67
Barrett esophagus cancer 0.6 0.3 1
benign prostatic hyperplasia 0.3 -0.3
Biofilm 2.4 2.4
Bipolar Disorder 1.8 1.7 0.06
Brain Trauma 0.9 1.4 -0.56
Breast Cancer 1.2 0.3 3
Cancer (General) 0.9 3.4 -2.78
Carcinoma 4.6 2.6 0.77
Celiac Disease 3 3.8 -0.27
Cerebral Palsy 1.4 1.3 0.08
Chronic Fatigue Syndrome 6 7.7 -0.28
Chronic Kidney Disease 4.6 2.9 0.59
Chronic Lyme 0.6 0.8 -0.33
Chronic Obstructive Pulmonary Disease (COPD) 2.4 2 0.2
Chronic Urticaria (Hives) 0.8 1.2 -0.5
Coagulation / Micro clot triggering bacteria 0.7 1.3 -0.86
Cognitive Function 3.6 1.6 1.25
Colorectal Cancer 9 2.5 2.6
Constipation 1.5 1.6 -0.07
Coronary artery disease 1.8 3 -0.67
COVID-19 10.3 14 -0.36
Crohn's Disease 8.7 5.8 0.5
Cushing's Syndrome (hypercortisolism) 0.9 -0.9
cystic fibrosis 1.9 -1.9
deep vein thrombosis 2.5 1.4 0.79
Denture Wearers Oral Shifts 2.1 2.1
Depression 11.8 9.3 0.27
Dermatomyositis 0.3 0.3 0
Eczema 1.7 3.2 -0.88
Endometriosis 2.3 2 0.15
Eosinophilic Esophagitis 0.3 0.6 -1
Epilepsy 2.8 1.7 0.65
erectile dysfunction 2 0.3 5.67
Fibromyalgia 3.7 3.6 0.03
Functional constipation / chronic idiopathic constipation 5.7 4.9 0.16
gallstone disease (gsd) 3.1 1.1 1.82
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 2.4 1.2 1
Generalized anxiety disorder 2.2 2.5 -0.14
giant cell arteritis 0.2 -0.2
Glioblastoma 0.3 -0.3
Gout 2.7 1.4 0.93
Graves' disease 1.9 3.3 -0.74
Gulf War Syndrome 0.9 1.5 -0.67
Halitosis 1.8 0.3 5
Hashimoto's thyroiditis 3.9 1.8 1.17
Heart Failure 4.4 2.5 0.76
hemorrhagic stroke 1.3 1.3
Hidradenitis Suppurativa 1.4 0.3 3.67
High Histamine/low DAO 1.3 0.6 1.17
hypercholesterolemia (High Cholesterol) 0.5 0.5
hyperglycemia 1.2 1.1 0.09
Hyperlipidemia (High Blood Fats) 0.9 0.3 2
hypersomnia 0.7 -0.7
hypertension (High Blood Pressure 4.1 6.3 -0.54
Hypothyroidism 1 -1
Hypoxia 2.4 0.9 1.67
IgA nephropathy (IgAN) 1.9 5.5 -1.89
Inflammatory Bowel Disease 9.9 10.4 -0.05
Insomnia 2.8 2.4 0.17
Intelligence 1.4 0.6 1.33
Intracranial aneurysms 1.4 0.9 0.56
Irritable Bowel Syndrome 7.7 5.3 0.45
ischemic stroke 2.6 1.1 1.36
Liver Cirrhosis 7.5 3.6 1.08
Long COVID 7.7 8.8 -0.14
Low bone mineral density 1.1 -1.1
Lung Cancer 0.9 1 -0.11
Lymphoma 0.3 0.3
Mast Cell Issues / mastitis 0.9 0.9 0
ME/CFS with IBS 1.1 2.4 -1.18
ME/CFS without IBS 2 2.4 -0.2
membranous nephropathy 0.3 0.3
Menopause 2.1 0.5 3.2
Metabolic Syndrome 7.8 8.5 -0.09
Mood Disorders 11.7 7.8 0.5
multiple chemical sensitivity [MCS] 1.2 0.1 11
Multiple Sclerosis 7.9 7 0.13
Multiple system atrophy (MSA) 1.2 0.7 0.71
myasthenia gravis 0.3 0.7 -1.33
neuropathic pain 0.3 3.1 -9.33
Neuropathy (all types) 0.7 2.5 -2.57
neuropsychiatric disorders (PANDAS, PANS) 0.6 0.6
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 5.3 4.8 0.1
NonCeliac Gluten Sensitivity 1.3 0.6 1.17
Obesity 10.6 8.9 0.19
obsessive-compulsive disorder 5.8 4.2 0.38
Osteoarthritis 2.7 1.2 1.25
Osteoporosis 2.5 1.6 0.56
pancreatic cancer 1.8 0.6 2
Parkinson's Disease 8.3 8.9 -0.07
Polycystic ovary syndrome 7.3 3.2 1.28
Postural orthostatic tachycardia syndrome 0.2 0.6 -2
Premenstrual dysphoric disorder 0.7 0.4 0.75
primary biliary cholangitis 1.2 1.7 -0.42
Primary sclerosing cholangitis 3 3.2 -0.07
Psoriasis 3.3 3.4 -0.03
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 8.5 4.7 0.81
Rosacea 1.2 1 0.2
Schizophrenia 7.2 3.1 1.32
scoliosis 0.3 1.2 -3
Sjögren syndrome 2.6 3.2 -0.23
Sleep Apnea 2.2 1.8 0.22
Slow gastric motility / Gastroparesis 0.9 0.3 2
Small Intestinal Bacterial Overgrowth (SIBO) 1.6 0.6 1.67
Stress / posttraumatic stress disorder 2.6 2.7 -0.04
Systemic Lupus Erythematosus 4.3 2.4 0.79
Tic Disorder 1.5 1.8 -0.2
Tourette syndrome 0.9 0.3 2
Type 1 Diabetes 5.1 4.4 0.16
Type 2 Diabetes 8.8 7.9 0.11
Ulcerative colitis 6.4 7.7 -0.2
Unhealthy Ageing 6.8 2.4 1.83
Vitiligo 2.5 1.5 0.67

Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.

Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served.   Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA   Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.   Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.   Inventions /Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]